Latest filing published 29 Mar 2021 for Cardiff Oncology, Inc., €25k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -72.9%Entry US$9.10 · Close at T+365 US$2.47
- +315.8%Entry US$2.02 · Close at T+365 US$8.40
- -47.9%Entry US$4.86 · Close at T+365 US$2.53
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Rodney S. Markin: trading record in brief
Rodney S. Markin is a declared insider of Cardiff Oncology, Inc., with filings sourced from SEC (Form 4). Between 2 September 2017 and 26 March 2021, the trades on record add up to 6 filings.
Every open-market trade on record is a purchase: 4 purchases worth €114k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 2 option exercises. Since January 2021: 1 purchase and no sales on the market.
Half of the purchases are above €29k and half below. Clusters matter here: 4 out of 4 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 3 purchases show a median change of +1.2%, with the price up in 67% of them. They describe history only and say nothing certain about the share price ahead.
The newest entry dates from 29 March 2021: an open-market purchase of €25k, in Cardiff Oncology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Rodney S. Markin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 2,900 shares@ US$10.3230.5% of flowCommon StockSEC:0001628280-21-005926:0Canonical exit: 24 Jun 2021 (T+90)
- 20,979 shares@ US$1.43100.0% of flowCommon StockSEC:0001104659-20-063181:0Canonical exit: 12 Aug 2020 (T+90)
- 41,200 shares@ US$0.8552.1% of flowCommon StockSEC:0000899243-18-017592:0Canonical exit: 18 Sept 2018 (T+90)
- 16,667 shares0Common StockSEC:0000899243-18-000480:0
- 5,943 shares0Common StockSEC:0001104659-17-055889:0
5 of 5 declarations